dc.contributor.author | Diaz-Beya, Marina | |
dc.contributor.author | Brunet, S | |
dc.contributor.author | Nomdedeu, J | |
dc.contributor.author | Cordeiro, Anna | |
dc.contributor.author | Tormo, M | |
dc.contributor.author | Escoda, Lourdes | |
dc.contributor.author | Ribera, J. M | |
dc.contributor.author | Arnan, M | |
dc.contributor.author | Heras, Inmaculada | |
dc.contributor.author | Gallardo, David | |
dc.contributor.author | Bargay Lleonart, Joan | |
dc.contributor.author | Queipo de Llano, Maria Paz | |
dc.contributor.author | Salamero, O | |
dc.contributor.author | Marti, J. M | |
dc.contributor.author | Sampol Mayol, Antonia | |
dc.contributor.author | Pedro, C | |
dc.contributor.author | Hoyos, M | |
dc.contributor.author | Pratcorona, M | |
dc.contributor.author | Castellano, JJ | |
dc.contributor.author | Nomdedeu, M | |
dc.contributor.author | Risueno, RM | |
dc.contributor.author | Sierra, J | |
dc.contributor.author | Monzo, M | |
dc.contributor.author | Navarro, A | |
dc.contributor.author | Esteve, Jordi | |
dc.date.accessioned | 2024-07-04T12:56:29Z | |
dc.date.available | 2024-07-04T12:56:29Z | |
dc.date.issued | 2015-10 | |
dc.identifier.citation | Diaz-Beya M, Brunet S, Nomdedeu J, Cordeiro A, Tormo M, Escoda L, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. Blood Cancer J. 2015 Oct;5:e352. | en |
dc.identifier.issn | 2044-5385 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/10668 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/20149 | |
dc.description.abstract | Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (>= 60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P = 0.0025), shorter leukemia-free survival (P = 0.026) and higher cumulative incidence of relapse (P = 0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P = 0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML. | en |
dc.description.sponsorship | Marina Diaz-Beya is supported by ISCIII (Rio Hortega CM13/00205). This research was in part supported by Fundacion Espanola de Hematologia y Hemoterapia (beca de investigacion MDB). This research is also supported by grants from Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III PI13/00999 (PI: JE), RETICS RD12/0036/0010 (JE; MDB) and SDCSD from School of Medicine, University of Barcelona, AECC-Catalunya 2013 (AN) (sponsored by Mat Holding), and grants AGAUR 2014SGR-1281, ISCIII RD12/0036/0071 and PI014/00450 (JS). Anna Cordeiro is an APIF fellow of the University of Barcelona. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Nature Publishing Group | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Disease-Free Survival | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Kaplan-Meier Estimate | * |
dc.subject.mesh | Young Adult | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Leukemia, Myeloid, Acute | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Adolescent | * |
dc.subject.mesh | Cytogenetic Analysis | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Prognosis | * |
dc.subject.mesh | Transcriptome | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | MicroRNAs | * |
dc.subject.mesh | Neoplasm Proteins | * |
dc.subject.mesh | Biomarkers, Tumor | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Risk Factors | * |
dc.subject.mesh | Proportional Hazards Models | * |
dc.title | The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia | en |
dc.type | research article | en |
dc.rights.license | Attribution 4.0 International | * |
dc.identifier.pubmedID | 26430723 | es_ES |
dc.format.volume | 5 | es_ES |
dc.format.page | e352 | es_ES |
dc.identifier.doi | 10.1038/bcj.2015.76 | |
dc.relation.publisherversion | https://dx.doi.org/10.1038/bcj.2015.76 | en |
dc.identifier.journal | Blood Cancer Journal | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Modelos de Riesgos Proporcionales | * |
dc.subject.decs | Análisis Citogenético | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Biomarcadores de Tumor | * |
dc.subject.decs | Adolescente | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Proteínas de Neoplasias | * |
dc.subject.decs | Factores de Riesgo | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Adulto Joven | * |
dc.subject.decs | Estimación de Kaplan-Meier | * |
dc.subject.decs | Pronóstico | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Adulto | * |
dc.subject.decs | Leucemia Mieloide Aguda | * |
dc.subject.decs | Supervivencia sin Enfermedad | * |
dc.subject.decs | MicroARNs | * |
dc.subject.decs | Transcriptoma | * |
dc.identifier.scopus | 2-s2.0-84943169416 | |
dc.identifier.wos | 368920300002 | |
dc.identifier.pui | L606212831 | |